Literature DB >> 28449519

Postoperative radiotherapy and lung cancer in stage III: helpful or harmful.

Francesco Fiorica1.   

Abstract

Entities:  

Year:  2017        PMID： 28449519      PMCID： PMC5394061          DOI： 10.21037/jtd.2017.02.76

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  6 in total

1.  Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection.

Authors:  Charlotte Billiet; Stéphanie Peeters; Herbert Decaluwé; Johan Vansteenkiste; Christophe Dooms; Christophe M Deroose; Marc Hendrikx; Paul De Leyn; Paul Bulens; Rezaul Karim; Cécile Le Péchoux; Jeroen Mebis; Dirk De Ruysscher
Journal:  J Thorac Oncol       Date:  2016-07-05       Impact factor: 15.609

2.  Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.

Authors:  Cliff G Robinson; Aalok P Patel; Jeffrey D Bradley; Todd DeWees; Saiama N Waqar; Daniel Morgensztern; Maria Q Baggstrom; Ramaswamy Govindan; Jennifer M Bell; Tracey J Guthrie; Graham A Colditz; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; G Alexander Patterson; Bryan F Meyers; Varun Puri
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

3.  In Regard to Ramroth et al.

Authors:  Francesco Fiorica
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-01-01       Impact factor: 7.038

Review 4.  Postoperative radiotherapy for non-small cell lung cancer.

Authors:  Sarah Burdett; Larysa Rydzewska; Jayne Tierney; David Fisher; Mahesh Kb Parmar; Rodrigo Arriagada; Jean Pierre Pignon; Cecile Le Pechoux
Journal:  Cochrane Database Syst Rev       Date:  2016-10-11

5.  Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline.

Authors:  George Rodrigues; Hak Choy; Jeffrey Bradley; Kenneth E Rosenzweig; Jeffrey Bogart; Walter J Curran; Elizabeth Gore; Corey Langer; Alexander V Louie; Stephen Lutz; Mitchell Machtay; Varun Puri; Maria Werner-Wasik; Gregory M M Videtic
Journal:  Pract Radiat Oncol       Date:  2015 May-Jun

6.  Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer.

Authors:  Tao Lei; Xiao-Ling Xu; Wei Chen; Ya-Ping Xu; Wei-Min Mao
Journal:  Onco Targets Ther       Date:  2016-02-24       Impact factor: 4.147
  6 in total
  1 in total

1.  A closer look at the safety and effectiveness of modern PORT in stage III-N2 non-small cell lung cancer.

Authors:  Charlotte Billiet; Dirk De Ruysscher
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.